Merit Medical Systems has acquired View Point Medical, Inc. for approximately $140 million ($90 million cash at closing plus $25 million deferred payments over two years). View Point manufactures the OneMark Detection Imaging System for breast and soft tissue tumor localization. The acquisition is expected to be dilutive to Merit's 2026 earnings but accretive in 2027 and beyond, with projected revenue contribution of $2-4 million in 2026 and $14-16 million in 2027.

The global uterine fibroid market is projected to grow from USD 5.26 billion in 2025 to USD 9.43 billion by 2033 at a CAGR of 7.63%. Growth is driven by rising prevalence of fibroids (affecting 70-80% of women by age 50), technological advances in minimally invasive procedures with 60% adoption increase, and expanded healthcare infrastructure in emerging markets. Minimally invasive procedures and MRI-guided focused ultrasound are expected to see the fastest growth rates.

Merit, a global engagement and incentives technology company headquartered in Riyadh, has acquired Synchro Marketing, an Australian leader in sales incentive programs for automotive and oil & gas sectors. The acquisition accelerates Merit's global expansion and enhances its sector-specific capabilities, particularly in the APAC region. Synchro will continue operating under current leadership while integrating into Merit's global platform.

Merit Medical Systems has signed an asset purchase agreement with PENTAX Medical to acquire the C2 CryoBalloon device for $22 million, expanding its endoscopy portfolio in the gastroenterology market with technology to treat Barrett's esophagus and other gastrointestinal disorders.

Merit Medicine has integrated Willis Towers Watson's HealthMAPS® manuals into its Merit Predict predictive analytics solution, enabling more precise group health risk assessment by combining actuarial expertise with advanced predictive modeling.

Merit Medical received CE Mark approval for Embosphere Microspheres to treat knee osteoarthritis through genicular artery embolisation, offering a minimally invasive pain management option with proven clinical success.

Merit Medical Systems reported strong Q2 2025 financial results, with revenue of $382.5 million (up 13.2%), beating analyst estimates. The company showed robust growth in cardiovascular and endoscopy device segments and raised its full-year guidance.

The global blood pressure monitor market is projected to grow from USD 2.40 billion in 2025 to USD 4.36 billion by 2035, driven by aging populations, home healthcare, and AI-powered wearables. The rising prevalence of hypertension and technological advancements are key factors driving the market growth.

Merit Medical Systems announced the resignation of its President, Joseph C. Wright, effective January 3, 2025, following an investigation into allegations regarding his conduct. The company's Board of Directors has re-appointed Fred P. Lampropoulos as the new President.

The global guidewires market is expected to grow from $4.15 billion in 2024 to $6.89 billion by 2034, driven by increased demand for minimally invasive procedures and technological advancements in guidewire materials and design.

Merit Medical Systems agreed to acquire Cook Medical's lead management business for $210 million, aiming to strengthen its position in the cardiac intervention market. The deal is expected to dilute Merit's financial metrics in the short term.

Merit Medical Systems, Inc. has signed an agreement to acquire Cook Medical's lead management portfolio for $210 million, which is expected to add around $40 million in revenue annually starting in 2025 and strengthen Merit's electrophysiology and cardiac rhythm management business.